AMEX · CLDI
Healthcare · Biotechnology
$1.63
Down-$0.05 (-3.07%)
Updated Aug 13, 2026, 6:33 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CLDI closed at $1.63 after 20 trading sessions, up 1226.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.63 | $1.6363 | $1.57 | $1.63 | 113.25K |
| Aug 11, 2026 | $1.63 | $1.70 | $1.5575 | $1.64 | 232.54K |
| Aug 10, 2026 | $1.63 | $1.70 | $1.605 | $1.63 | 163.58K |
| Aug 7, 2026 | $1.79 | $1.79 | $1.57 | $1.62 | 204.67K |
| Aug 6, 2026 | $1.75 | $1.879 | $1.73 | $1.79 | 253.95K |
| Aug 5, 2026 | $1.87 | $1.87 | $1.68 | $1.76 | 171.03K |
| Aug 4, 2026 | $1.63 | $1.91 | $1.6286 | $1.89 | 275.52K |
| Aug 3, 2026 | $1.62 | $1.69 | $1.53 | $1.68 | 264.46K |
| Jul 31, 2026 | $1.93 | $1.93 | $1.53 | $1.64 | 464.48K |
| Jul 29, 2026 | $1.6048 | $1.6176 | $1.4832 | $1.4928 | 146.61K |
| Jul 28, 2026 | $1.7152 | $1.752 | $1.6112 | $1.7184 | 159.04K |
| Jul 27, 2026 | $1.6032 | $1.9024 | $1.5504 | $1.752 | 462.65K |
| Jul 24, 2026 | $0.1055 | $0.1109 | $0.0952 | $0.10 | 40.14M |
| Jul 23, 2026 | $0.104 | $0.1106 | $0.098 | $0.105 | 53.99M |
| Jul 22, 2026 | $0.095 | $0.11 | $0.095 | $0.1056 | 2.84M |
| Jul 21, 2026 | $0.10 | $0.1039 | $0.097 | $0.0995 | 4.14M |
| Jul 20, 2026 | $0.1246 | $0.125 | $0.115 | $0.1156 | 3.51M |
| Jul 17, 2026 | $0.116 | $0.125 | $0.114 | $0.1189 | 1.73M |
| Jul 16, 2026 | $0.1225 | $0.1275 | $0.1143 | $0.1156 | 1.78M |
| Jul 15, 2026 | $0.12 | $0.1247 | $0.1177 | $0.1229 | 1.49M |
The latest Smart Investors Daily articles mentioning CLDI.
CLDI research
Company profile and research snapshot.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 27, 2024 | Ladenburg Thalmann | Buy | — |
| May 15, 2024 | Baird | Outperform | — |
| Mar 21, 2024 | HC Wainwright & Co. | Buy | — |
| Mar 21, 2024 | Baird | Outperform | — |
| Nov 22, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 27, 2026
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on
Benzinga · Jun 24, 2026
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell
Benzinga · Jun 16, 2026
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it has received pre-IND regulatory feedback
Benzinga · Feb 20, 2026
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLDI.
